Current Status and Future Prospects for Esophageal Cancer Treatment

Overview

Journal Ann Thorac Cardiovasc Surg

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2016 Dec 23

PMID 28003586

Citations 90

Authors

Makoto Sohda

Hiroyuki Kuwano

Affiliations

Soon will be listed here.

Abstract

The local control effect of esophagectomy with three-field lymph node dissection (3FLD) is reaching its limit pending technical advancement. Minimally invasive esophagectomy (MIE) by thoracotomy is slowly gaining acceptance due to advantages in short-term outcomes. Although the evidence is slowly increasing, MIE is still controversial. Also, the results of treatment by surgery alone are limiting, and multimodality therapy, which includes surgical and non-surgical treatment options including chemotherapy, radiotherapy, and endoscopic treatment, has become the mainstream therapy. Esophagectomy after neoadjuvant chemotherapy (NAC) is the standard treatment for clinical stages II/III (except for T4) esophageal cancer, whereas chemoradiotherapy (CRT) is regarded as the standard treatment for patients who wish to preserve their esophagus, those who refuse surgery, and those with inoperable disease. CRT is also usually selected for clinical stage IV esophageal cancer. On the other hand, with the spread of CRT, salvage esophagectomy has traditionally been recognized as a feasible option; however, many clinicians oppose the use of surgery due to the associated unfavorable morbidity and mortality profile. In the future, the improvement of each treatment result and the establishment of individual strategies are important although esophageal cancer has many treatment options.

Citing Articles

Identification of biomarkers and potential drug targets for esophageal cancer: a Mendelian randomization study.

Li C, Cui X, Ren M, Yin Y, He S Sci Rep. 2025; 15(1):8176.

PMID: 40059241 PMC: 11891310. DOI: 10.1038/s41598-025-93068-4.

Inspiratory Muscle Training Before Esophagectomy Increases Diaphragmatic Excursion: A Randomized Controlled Trial.

Mizusawa H, Higashimoto Y, Shiraishi O, Shiraishi M, Sugiya R, Noguchi M Ann Surg Oncol. 2024; 31(13):9352-9361.

PMID: 39283579 DOI: 10.1245/s10434-024-16180-1.

Short-term outcomes of three- and two-field lymphadenectomy with minimally invasive esophagectomy for esophageal cancer: a propensity score-matching analysis.

Sun Z, Fan B, Liu J, Di S, Yue C, Zhao J Transl Cancer Res. 2024; 13(7):3437-3445.

PMID: 39145057 PMC: 11319954. DOI: 10.21037/tcr-23-2356.

Assessment of Narrow-Band Imaging Algorithm for Video Capsule Endoscopy Based on Decorrelated Color Space for Esophageal Cancer: Part II, Detection and Classification of Esophageal Cancer.

Fang Y, Huang C, Karmakar R, Mukundan A, Tsao Y, Yang K Cancers (Basel). 2024; 16(3).

PMID: 38339322 PMC: 10854620. DOI: 10.3390/cancers16030572.

Cranberry Proanthocyanidins Mitigate Reflux-Induced Transporter Dysregulation in an Esophageal Adenocarcinoma Model.

Zhang Y, Weh K, Tripp B, Clarke J, Howard C, Sunilkumar S Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139823 PMC: 10747310. DOI: 10.3390/ph16121697.

References

Crosby T, Hurt C, Falk S, Gollins S, Mukherjee S, Staffurth J . Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013; 14(7):627-37. DOI: 10.1016/S1470-2045(13)70136-0. View

Biere S, van Berge Henegouwen M, Maas K, Bonavina L, Rosman C, Garcia J . Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012; 379(9829):1887-92. DOI: 10.1016/S0140-6736(12)60516-9. View

Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Ishiyama H . A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501). Radiother Oncol. 2008; 87(3):398-404. DOI: 10.1016/j.radonc.2008.03.006. View

Miyazaki T, Sohda M, Tanaka N, Suzuki S, Ieta K, Sakai M . Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2014; 75(3):449-55. DOI: 10.1007/s00280-014-2659-6. View

Nagpal K, Ahmed K, Vats A, Yakoub D, James D, Ashrafian H . Is minimally invasive surgery beneficial in the management of esophageal cancer? A meta-analysis. Surg Endosc. 2010; 24(7):1621-9. DOI: 10.1007/s00464-009-0822-7. View

Lee J, Lee K, Im Y, Kang W, Park K, Kim K . Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2005; 80(4):1170-5. DOI: 10.1016/j.athoracsur.2005.03.058. View

Oyama T, Tomori A, Hotta K, Morita S, Kominato K, Tanaka M . Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol. 2005; 3(7 Suppl 1):S67-70. DOI: 10.1016/s1542-3565(05)00291-0. View

van der Sluis P, Ruurda J, Verhage R, van der Horst S, Haverkamp L, Siersema P . Oncologic Long-Term Results of Robot-Assisted Minimally Invasive Thoraco-Laparoscopic Esophagectomy with Two-Field Lymphadenectomy for Esophageal Cancer. Ann Surg Oncol. 2015; 22 Suppl 3:S1350-6. PMC: 4686562. DOI: 10.1245/s10434-015-4544-x. View

Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T . Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol. 2009; 100(6):442-6. DOI: 10.1002/jso.21353. View

10.

Nomura M, Oze I, Abe T, Komori A, Narita Y, Masuishi T . Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. Cancer Chemother Pharmacol. 2015; 76(2):357-63. DOI: 10.1007/s00280-015-2806-8. View

11.

Takahashi H, Arimura Y, Masao H, Okahara S, Tanuma T, Kodaira J . Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc. 2010; 72(2):255-64, 264.e1-2. DOI: 10.1016/j.gie.2010.02.040. View

12.

Fujishiro M, Yahagi N, Kakushima N, Kodashima S, Muraki Y, Ono S . Endoscopic submucosal dissection of esophageal squamous cell neoplasms. Clin Gastroenterol Hepatol. 2006; 4(6):688-94. DOI: 10.1016/j.cgh.2006.03.024. View

13.

Funakawa K, Uto H, Sasaki F, Nasu Y, Mawatari S, Arima S . Effect of endoscopic submucosal dissection for superficial esophageal neoplasms and risk factors for postoperative stricture. Medicine (Baltimore). 2015; 94(1):e373. PMC: 4602840. DOI: 10.1097/MD.0000000000000373. View

14.

Takahashi H, Arimura Y, Okahara S, Kodaira J, Hokari K, Tsukagoshi H . A randomized controlled trial of endoscopic steroid injection for prophylaxis of esophageal stenoses after extensive endoscopic submucosal dissection. BMC Gastroenterol. 2015; 15:1. PMC: 4308850. DOI: 10.1186/s12876-014-0226-6. View

15.

Bosset J, GIGNOUX M, Triboulet J, Tiret E, Mantion G, Elias D . Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997; 337(3):161-7. DOI: 10.1056/NEJM199707173370304. View

16.

Sudarshan M, Alcindor T, Ades S, Aloraini A, van Huyse M, Asselah J . Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma. Ann Surg Oncol. 2014; 22(1):324-30. DOI: 10.1245/s10434-014-3875-3. View

17.

Ui T, Fujii H, Hosoya Y, Nagase M, Mieno M, Mori M . Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus. Dis Esophagus. 2014; 28(2):180-7. DOI: 10.1111/dote.12187. View

18.

Isomoto H, Yamaguchi N, Nakayama T, Hayashi T, Nishiyama H, Ohnita K . Management of esophageal stricture after complete circular endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. BMC Gastroenterol. 2011; 11:46. PMC: 3111579. DOI: 10.1186/1471-230X-11-46. View

19.

Kinjo Y, Kurita N, Nakamura F, Okabe H, Tanaka E, Kataoka Y . Effectiveness of combined thoracoscopic-laparoscopic esophagectomy: comparison of postoperative complications and midterm oncological outcomes in patients with esophageal cancer. Surg Endosc. 2011; 26(2):381-90. DOI: 10.1007/s00464-011-1883-y. View

20.

Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y . Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994; 220(3):364-72; discussion 372-3. PMC: 1234394. DOI: 10.1097/00000658-199409000-00012. View